These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26324402)

  • 1. Improving Cross-Sector Comparisons: Going Beyond the Health-Related QALY.
    Brazier J; Tsuchiya A
    Appl Health Econ Health Policy; 2015 Dec; 13(6):557-65. PubMed ID: 26324402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the monetary value of a QALY: a new approach based on UK data.
    Mason H; Jones-Lee M; Donaldson C
    Health Econ; 2009 Aug; 18(8):933-50. PubMed ID: 18855880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is subjective well-being a useful parameter for allocating resources among public interventions?
    Gandjour A
    Health Care Anal; 2001; 9(4):437-47. PubMed ID: 11874257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Searchers vs surveyors in estimating the monetary value of a QALY: resolving a nasty dilemma for NICE.
    Baker R; Chilton S; Donaldson C; Jones-Lee M; Lancsar E; Mason H; Metcalf H; Pennington M; Wildman J
    Health Econ Policy Law; 2011 Oct; 6(4):435-47. PubMed ID: 21854688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating a WTP-based value of a QALY: the 'chained' approach.
    Robinson A; Gyrd-Hansen D; Bacon P; Baker R; Pennington M; Donaldson C;
    Soc Sci Med; 2013 Sep; 92():92-104. PubMed ID: 23849283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can we estimate the 'social' value of a QALY? Four core issues to resolve.
    Smith RD; Richardson J
    Health Policy; 2005 Sep; 74(1):77-84. PubMed ID: 16098414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Economic examination of the 2006/7 update of the Israeli national list of health services].
    Shmueli A; Nissan-Englcin E
    Harefuah; 2008 Jun; 147(6):488-92, 576. PubMed ID: 18693622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of social care for adults: developing a preference-weighted measure.
    Netten A; Burge P; Malley J; Potoglou D; Towers AM; Brazier J; Flynn T; Forder J; Wall B
    Health Technol Assess; 2012; 16(16):1-166. PubMed ID: 22459668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation.
    King JT; Tsevat J; Lave JR; Roberts MS
    Med Decis Making; 2005; 25(6):667-77. PubMed ID: 16282217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness versus cost-utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter?
    Tengs TO
    Value Health; 2004; 7(1):70-8. PubMed ID: 14720132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A welfare economic approach to measure outcomes in stuttering: comparing willingness to pay and quality adjusted life years.
    Franic DM; Bothe AK; Bramlett RE
    J Fluency Disord; 2012 Dec; 37(4):300-13. PubMed ID: 23218213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health outcomes in economic evaluation: the QALY and utilities.
    Whitehead SJ; Ali S
    Br Med Bull; 2010; 96():5-21. PubMed ID: 21037243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A utility-theoretic model for QALYs and willingness to pay.
    Klose T
    Health Econ; 2003 Jan; 12(1):17-31. PubMed ID: 12483758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Values and evidence colliding: health technology assessment in child health.
    Ungar WJ; Prosser LA; Burnett HF
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):417-9. PubMed ID: 23977967
    [No Abstract]   [Full Text] [Related]  

  • 15. Measurement of utility.
    Thavorncharoensap M
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S43-9. PubMed ID: 24964698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation.
    Bobinac A; van Exel NJ; Rutten FF; Brouwer WB
    J Health Econ; 2012 Jan; 31(1):158-68. PubMed ID: 22018622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis.
    Byrne MM; O'malley K; Suarez-Almazor ME
    Med Decis Making; 2005; 25(6):655-66. PubMed ID: 16282216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trying to estimate a monetary value for the QALY.
    Pinto-Prades JL; Loomes G; Brey R
    J Health Econ; 2009 May; 28(3):553-62. PubMed ID: 19327857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
    Braithwaite RS; Meltzer DO; King JT; Leslie D; Roberts MS
    Med Care; 2008 Apr; 46(4):349-56. PubMed ID: 18362813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Willingness to pay for a QALY.
    Gyrd-Hansen D
    Health Econ; 2003 Dec; 12(12):1049-60. PubMed ID: 14673813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.